Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.

Trial Details

NCT ID

NCT07006077

Phase

PHASE2

Sponsor

Hangzhou Converd Co., Ltd.

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Recombinant human IL-21-expressing oncolytic vaccinia virus injection

Locations (sample)

Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

Signing an informed consent form.
Men or women aged 18 to 75 years.
Histologically and/or cytologically confirmed advanced malignant advanced pancreatic tumors refractory or failed to respond to standard therapy (in…
At least one measurable lesion according to RECIST v1.1 criteria, which can be injected intratumorally either directly or with the assistance of En…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →